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OBJECTIVES: To evaluate primary nonadherence [PNA] to cholesterol medications
and compare health care outcomes between primary adherent and nonadherent
patients. METHODS: This retrospective cohort study identified all patients who
were treatment-naïve to antihyperlipidemics patients with at least one new cho-
lesterol prescription written during the period of December 1, 2009 to February 28,
2010. PNA was defined as the failure to fill a prescription within 90 days of when it
was written [index date]. Patients were followed for 18months after the index date
for healthcare outcomes of low-density lipoprotein [LDL] values, cardiac/stroke
events, ER visits and all-cause or cardiac/stroke-related hospitalizations. Descrip-
tive statistics were used to compare baseline characteristics and health care out-
comes between primary adherent and nonadherent patients. Cox proportional
hazard models were used to estimate the hazard ratio [HR] as a measure of the
relative risk of each event in the primary nonadherent in comparison to the pri-
mary adherent after controlling for patient and physician characteristics. Patients
were censored at the end of the follow-up period. RESULTS: A total 17,400 patients
were identified during the study period and 15% were primary nonadherent. At
baseline, primary nonadherent patients were sicker than primary adherent pa-
tients with significantly higher Charlson comorbidity index values, prescription
use, ER visits and hospitalizations in the prior year. LDL values decreased after the
index date for both groups, but primary adherent patients had a significantly
greater decrease in LDL values on average [-37.2 vs. -14.9 (p0.0001)]. After adjust-
ing for baseline covariates, the resulting HR (95%CI) was 0.83 (0.69, 0.99) for cardiac/
stroke events, 0.99 (0.91, 1.09) for ER visits, 0.87 (0.77, 0.99) for all-cause hospital-
ization, and 0.72 (0.44, 1.12) for CV-related hospitalization.CONCLUSIONS: Primary
nonadherent patients experienced smaller decreases in LDL values, but were not
found to be at increased risk for cardiac/stroke events, ER visits or hospitalization
during the follow-up period.
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OBJECTIVES: Treatment for high-prevalence chronic diseases requires medication
adherence. Improved adherence increases medication utilization, leading to
higher pharmacy costs. Higher adherence, however, may reduce medical services
use resulting in a decrease in overall healthcare costs despite the increase in phar-
macy costs. This study examined the impact of chronic medication adherence on
healthcare costs.METHODS:The study sampleswere three independent cohorts of
individuals with the separate conditions of diabetes, hypertension and hypercho-
lesterolemia, identified from a commercially insured health plan using integrated
medical and pharmacy claims data between January 1, 2007 and December 31,
2009. Claims information of each individualwas assessed for 12months from index
date (the first outpatient visit or hospitalization discharge date during 2008). Ad-
herence was measured using Proportion of Days Covered (PDC) as endorsed by
Pharmacy Quality Assurance (PQA). Healthcare costs (pharmacy, medical and total
costs) weremeasured at two levels: all-cause and condition-specific. A generalized
linear model with a gamma log link controlling for covariates was used to fit six
statistical models for each cohort. RESULTS: There were 22,012, 64,600, and 59,003
individuals in the diabetes, hypertension and hypercholesterolemia cohorts re-
spectively. At the all-cause level, increased PDC was significantly associated with
decreased medical costs across the three cohorts (p0.05). At the condition-spe-
cific level, increased PDCwas significantly associatedwith decreasedmedical costs
in the hypertension and hypercholesterolemia cohorts (p0.001), but with in-
creased medical cost in the diabetes cohort (p0.001). Due to the large increase in
pharmacy costs associated with higher PDC (p0.001), total healthcare costs were
increased (p0.001) both at all-cause and condition-specific levels in each cohort.
CONCLUSIONS: As adherence increases, the resulting savings in medical costs are
not able to offset the increase in pharmacy costs. Therefore, measures that aim to
lower pharmacy cost while preserving or improving adherence are needed.
PCV73
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OBJECTIVES: The risk of medication non-adherence to prescribed antihyperten-
sive medications in older adults is high in part due to forgetfulness, cognitive
deficits and difficultieswith opening the traditional vial packaging. The objective of
this study was to assess the effect of innovative calendar blister packaging tech-
nology incorporating a day or date feature on adherence with antihypertensive
medications in older adults aged 65 and above treated for dementia. METHODS:
Pharmacy dispensing data (12/2006 - 7/2009) from a large US mass merchandiser
were analyzed. This retrospective cohort study included older adults who filled
prescription for oral lisinopril or enalapril at a study pharmacy during 1 year before
(baseline period) and after the switch of lisinopril packaging from vials to CBP
(follow-up period) and also filled a prescription for dementia medications during
the study period. Cohorts were stratified into new users (no dispense date for ACE
inhibitors (ACEI) or similar drugs during the 360 days before baseline index fill) and
prevalent users ( 1 dispense date for lisinopril or enalapril during the 360 days
before baseline index fill). Medication possession ratio (MPR) was used to calculate
adherence. RESULTS: A total of 26,508 patients were eligible for the study with
44.6% having a Medicare insurance type plan. The sample comprised of 18,580
lisinopril users (CBP) and 7928 enalapril users (vial); 7523 were new ACEI users
(28.4%) and 18,985 prevalent ACEI users (71.6%). After adjusting for age, gender, US
census region, average daily pill burden, median household income, payer type,
and prescribing physician specialty. CBP use in new and prevalent medication
users was associated with 10% higher MPR rate as compared vial use.
CONCLUSIONS: Preliminary analysis showed that there was a difference in MPR in
between older adults aged 65 and above treated for dementia who received anti-
hypertensive medication in CBP as compared to vial packaging.
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OBJECTIVES: Reducing hospital readmission helps contain healthcare cost and
improve quality. The objective of this research is to explore the relationship be-
tween post-dischargemedication adherence andhospital readmission.METHODS:
A cohort study design was used to compare medication adherence rates among
patients discharged from the hospital following a COPD (Chronic Obstructive Pul-
monary Disease) or CHF (Congestive Heart Failure) related hospitalization. Data
fromMarketScan®Commercial Claims and Encounters dataset (Thomson Reuters,
New York, NY) for the period of January 1, 2008 to December 31, 2009 was used.
Inclusion criteria required that the patient be: (a) under age 64 (b) continuously
enrolled over the pre and post 180 days of first (index) admission; (c) had a hospital
admission during the first 6 months of 2009 for CHF (ICD9428xx or 40211,
N12,260) or for COPD (ICD9 490xx, 491xx, 492xx, 494xx, 496xx, N149,411). Re-
admission defined as being readmitted within 30 days of discharge. The exposure
of interest was a disease-related prescription claim following hospital discharge.
The primary outcome measured as a binary variable indicating hospital readmis-
sion within 30 days of initial discharge. Multivariate logistic regression analysis
was conducted controlling for previous hospital days (same disease), previous phy-
sician visits (same disease), co-morbidity, age, and gender. RESULTS: Patients lack-
ing post-discharge medication claims had higher rate of readmission (p0.01 for
both disease). The differences were 17% (20% vs. 3%) for CHF and 3% (6% vs. 3%) for
COPD patients. When controlling for confounders, CHF patients without claim
were 8 times more likely to be re-admitted (p0.01) than those with one. COPD
patients showed similar effect with smaller effect size (Odds Ratio 3.8, p0.01).
CONCLUSIONS: Patientswithout post-dischargemedication claims aremore likely
to be readmitted. To improve the quality of inpatient care, efforts should be made
to ensure patients adhere to medication regimes following hospital discharge.
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OBJECTIVES:Dynamic Panel Models (DPMs) capture time-varying adherence effect
as well as control for state-dependence and unobserved biases. We applied DPMs
to estimate the direct impact of adherence to diabetes medications on HbA1C and
adherence to hypertension medications on systolic blood pressures (SBP) and dia-
stolic blood pressures (DBP) for patients who have both type II diabetes and comor-
bid hypertension.METHODS:A retrospective cohort study for patients newly start-
ing oral diabetes or hypertension medication therapy between July 2006 and June
2007 with the pre-existing comorbid hypertension or diabetes prescription history
was conducted using administrative claims from a large physician group in South-
ern California (N4633). Time-varying medication adherence, covariates (prior
outcomes, experience in hypoglycemia, experience in hospitalization, occurrence
of micro- or macro-complications) and outcomes were measured every 6 months
over 33 months of follow-up period. Available lag dependent and independent
variables were used as instrumental variables. Parameter estimates were com-
pared using fixed effects (FE), random effects (RE), and DPMs. The validity of the
model specification was tested through 2nd order autocorrelation test and Sargan
test of overidentifying restrictions. RESULTS: Applying DPMs, medication adher-
ence, prior outcomes, and age showed significant impact on clinical outcomes. We
found a 10 percentage point increase in adherence was associated with a 0.05
percentage point decrease (p0.04) in HbA1C, a 0.62 mmHg decrease (p0.02) in
SBP, and a 0.47mmHg decrease in DBP (p0.002) applying DPMs. Using the FE or RE
models, the adherence impact became smaller. A 10 percentage point increase in
adherence was associated with a 0.04 percentage point decrease (p0.001) in
HbA1C, a 0.22 mmHg decrease (p0.001) in SBP, and a 0.13 mmHg decrease
(p0.001) in DBP applying the FE model. CONCLUSIONS: DPMs estimated higher
adherence to diabetes or hypertension medications improved clinical outcomes,
and the estimated impact was greater than the results from conventional models.
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